;PMID: 9816185
;source_file_1385.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:41..116] = [t:41..116]
;2)section:[e:120..202] = [t:120..202]
;3)section:[e:206..322] = [t:206..322]
;4)sentence:[e:326..419] = [t:326..419]
;5)sentence:[e:420..759] = [t:420..759]
;6)sentence:[e:760..806] = [t:760..806]
;7)sentence:[e:807..957] = [t:807..957]
;8)sentence:[e:959..1129] = [t:959..1129]
;9)sentence:[e:1130..1234] = [t:1130..1234]
;10)sentence:[e:1235..1360] = [t:1235..1360]
;11)sentence:[e:1362..1550] = [t:1362..1550]
;12)sentence:[e:1551..1780] = [t:1551..1780]
;13)sentence:[e:1781..1936] = [t:1781..1936]
;14)sentence:[e:1937..2157] = [t:1937..2157]
;15)section:[e:2161..2205] = [t:2161..2205]

;section 0 Span:0..36
;Clin Cancer Res  1996 Feb;2(2):411-8
(SEC
  (FRAG (NNP:[0..4] Clin) (NN:[5..11] Cancer) (NNP:[12..15] Res)
        (CD:[17..21] 1996) (-LRB-:[22..28] Feb;2-LRB-) (CD:[28..29] 2)
        (-RRB-:[29..30] -RRB-) (CD:[30..34] :411) (::[34..35] -) (CD:[35..36] 8)))

;sentence 1 Span:41..116
;Detection of K-ras mutations in lung carcinomas: relationship to prognosis.
;[54..59]:gene-rna:"K-ras"
;[73..88]:malignancy:"lung carcinomas"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[41..50] Detection))
      (PP (IN:[51..53] of)
        (NP (NN:[54..59] K-ras) (NNS:[60..69] mutations)))
      (PP-LOC (IN:[70..72] in)
        (NP (NN:[73..77] lung) (NNS:[78..88] carcinomas))))
    (::[88..89] :)
    (NP
      (NP (NN:[90..102] relationship))
      (PP (TO:[103..105] to)
        (NP (NN:[106..115] prognosis))))
    (.:[115..116] .)))

;section 2 Span:120..202
;Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried
; JM.
(SEC
  (FRAG (NNP:[120..129] Keohavong) (NNP:[130..131] P) (,:[131..132] ,)
        (NNP:[133..142] DeMichele) (NNP:[143..145] MA) (,:[145..146] ,)
        (NNP:[147..157] Melacrinos) (NNP:[158..160] AC) (,:[160..161] ,)
        (NNP:[162..172] Landreneau) (NNP:[173..175] RJ) (,:[175..176] ,)
        (NNP:[177..183] Weyant) (NNP:[184..186] RJ) (,:[186..187] ,)
        (NNP:[188..197] Siegfried) (NNP:[199..201] JM) (.:[201..202] .)))

;section 3 Span:206..322
;Department of Environmental and Occupational Health, University of
;Pittsburgh,  Pittsburgh, Pennsylvania 15238, USA.
(SEC
  (FRAG (NN:[206..216] Department) (IN:[217..219] of)
        (NNP:[220..233] Environmental) (CC:[234..237] and)
        (NNP:[238..250] Occupational) (NNP:[251..257] Health) (,:[257..258] ,)
        (NNP:[259..269] University) (IN:[270..272] of)
        (NNP:[273..283] Pittsburgh) (,:[283..284] ,) (NNP:[286..296] Pittsburgh)
        (,:[296..297] ,) (NNP:[298..310] Pennsylvania) (NNP:[311..316] 15238)
        (,:[316..317] ,) (NNP:[318..321] USA) (.:[321..322] .)))

;sentence 4 Span:326..419
;The K-ras mutation is one of the most common genetic alterations found in
;human  lung cancer.
;[330..335]:gene-rna:"K-ras"
;[407..418]:malignancy:"lung cancer"
(SENT
  (S
    (NP-SBJ (DT:[326..329] The) (NN:[330..335] K-ras) (NN:[336..344] mutation))
    (VP (VBZ:[345..347] is)
      (NP-PRD
        (NP (CD:[348..351] one))
        (PP (IN:[352..354] of)
          (NP
            (NP (DT:[355..358] the)
              (ADJP (RBS:[359..363] most) (JJ:[364..370] common))
              (JJ:[371..378] genetic) (NNS:[379..390] alterations))
            (VP (VBN:[391..396] found)
              (NP (-NONE-:[396..396] *))
              (PP (IN:[397..399] in)
                (NP (JJ:[400..405] human)
                   (NN:[407..411] lung) (NN:[412..418] cancer))))))))
    (.:[418..419] .)))

;sentence 5 Span:420..759
;To evaluate the prognostic value of ras gene alterations in lung  cancer in a
;U.S. population, we have screened 173 human lung tumors, which  included 127
;adenocarcinomas, 37 squamous carcinomas, and 9 adenosquamous  carcinomas, for
;mutations in the K-ras gene using the combination of the PCR and  denaturing
;gradient gel electrophoresis.
;[456..459]:gene-rna:"ras"
;[480..492]:malignancy:"lung  cancer"
;[542..553]:malignancy:"lung tumors"
;[575..590]:malignancy:"adenocarcinomas"
;[595..614]:malignancy:"squamous carcinomas"
;[622..647]:malignancy:"adenosquamous  carcinomas"
;[670..675]:gene-rna:"K-ras"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[420..420] *))
      (VP (TO:[420..422] To)
        (VP (VB:[423..431] evaluate)
          (NP
            (NP (DT:[432..435] the) (JJ:[436..446] prognostic)
                (NN:[447..452] value))
            (PP (IN:[453..455] of)
              (NP (NN:[456..459] ras) (NN:[460..464] gene)
                  (NNS:[465..476] alterations)))
            (PP (IN:[477..479] in)
              (NP (NN:[480..484] lung) (NN:[486..492] cancer))))
          (PP (IN:[493..495] in)
            (NP (DT:[496..497] a) (NNP:[498..502] U.S.)
                (NN:[503..513] population))))))
    (,:[513..514] ,)
    (NP-SBJ (PRP:[515..517] we))
    (VP (VBP:[518..522] have)
      (VP (VBN:[523..531] screened)
        (NP
          (NP (CD:[532..535] 173) (JJ:[536..541] human)
             (NN:[542..546] lung) (NNS:[547..553] tumors))
          (,:[553..554] ,)
          (SBAR
            (WHNP-1 (WDT:[555..560] which))
            (S
              (NP-SBJ-1 (-NONE-:[560..560] *T*))
              (VP (VBD:[562..570] included)
                (NP
                  (NP (CD:[571..574] 127) (NNS:[575..590] adenocarcinomas))
                  (,:[590..591] ,)
                  (NP (CD:[592..594] 37)
                     (JJ:[595..603] squamous) (NNS:[604..614] carcinomas))
                  (,:[614..615] ,) (CC:[616..619] and)
                  (NP (CD:[620..621] 9)
                     (JJ:[622..635] adenosquamous) (NNS:[637..647] carcinomas)))))))
        (,:[647..648] ,)
        (PP (IN:[649..652] for)
          (NP
            (NP (NNS:[653..662] mutations))
            (PP-LOC (IN:[663..665] in)
              (NP (DT:[666..669] the) (NN:[670..675] K-ras) (NN:[676..680] gene)))))
        (S-MNR
          (NP-SBJ (-NONE-:[680..680] *))
          (VP (VBG:[681..686] using)
            (NP
              (NP (DT:[687..690] the) (NN:[691..702] combination))
              (PP (IN:[703..705] of)
                (NP
                  (NP (DT:[706..709] the) (NN:[710..713] PCR))
                  (CC:[714..717] and)
                  (NP (VBG:[719..729] denaturing) (NN:[730..738] gradient)
                      (NN:[739..742] gel) (NN:[743..758] electrophoresis)))))))))
    (.:[758..759] .)))

;sentence 6 Span:760..806
;Forty-three tumors contained K-ras  mutations.
;[772..778]:malignancy:"tumors"
;[789..794]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (CD:[760..771] Forty-three) (NNS:[772..778] tumors))
    (VP (VBD:[779..788] contained)
      (NP (NN:[789..794] K-ras) (NNS:[796..805] mutations)))
    (.:[805..806] .)))

;sentence 7 Span:807..957
;Of these, 41 were identified among the adenocarcinomas (32%), 1 among  the
;squamous carcinomas (2.7%), and 1 among the adenosquamous carcinomas (11%).
;[846..861]:malignancy:"adenocarcinomas"
;[882..901]:malignancy:"squamous carcinomas"
;[926..950]:malignancy:"adenosquamous carcinomas"
(SENT
  (S
    (S
      (PP (IN:[807..809] Of)
        (NP (DT:[810..815] these)))
      (,:[815..816] ,)
      (NP-SBJ-3=1 (CD:[817..819] 41))
      (VP (VBD:[820..824] were)
        (VP (VBN:[825..835] identified)
          (NP-3 (-NONE-:[835..835] *))
          (PP=2 (IN:[836..841] among)
            (NP (DT:[842..845] the) (NNS:[846..861] adenocarcinomas)
              (PRN (-LRB-:[862..863] -LRB-)
                (NP (CD:[863..865] 32) (NN:[865..866] %))
                (-RRB-:[866..867] -RRB-)))))))
    (,:[867..868] ,)
    (S
      (NP-SBJ=1 (CD:[869..870] 1))
      (PP=2 (IN:[871..876] among)
        (NP (DT:[878..881] the)
           (JJ:[882..890] squamous) (NNS:[891..901] carcinomas)
          (PRN (-LRB-:[902..903] -LRB-)
            (NP (CD:[903..906] 2.7) (NN:[906..907] %))
            (-RRB-:[907..908] -RRB-)))))
    (,:[908..909] ,) (CC:[910..913] and)
    (S
      (NP-SBJ=1 (CD:[914..915] 1))
      (PP=2 (IN:[916..921] among)
        (NP (DT:[922..925] the)
           (JJ:[926..939] adenosquamous) (NNS:[940..950] carcinomas)
          (PRN (-LRB-:[951..952] -LRB-)
            (NP (CD:[952..954] 11) (NN:[954..955] %))
            (-RRB-:[955..956] -RRB-)))))
    (.:[956..957] .)))

;sentence 8 Span:959..1129
;Forty of these mutations were found in codon 12 and consisted of 24 G to T 
;transversions, 12 G to A transitions, 2 G to C transversions, and 1 double GG
;to  TT mutation.
;[998..1006]:variation-location:"codon 12"
;[1027..1028]:variation-state-original:"G"
;[1032..1033]:variation-state-altered:"T"
;[1035..1048]:variation-type:"transversions"
;[1053..1054]:variation-state-original:"G"
;[1058..1059]:variation-state-altered:"A"
;[1060..1071]:variation-type:"transitions"
;[1075..1076]:variation-state-original:"G"
;[1080..1081]:variation-state-altered:"C"
;[1082..1095]:variation-type:"transversions"
;[1110..1112]:variation-state-original:"GG"
;[1117..1119]:variation-state-altered:"TT"
;[1120..1128]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[959..964] Forty))
      (PP (IN:[965..967] of)
        (NP (DT:[968..973] these) (NNS:[974..983] mutations))))
    (VP
      (VP (VBD:[984..988] were)
        (VP (VBN:[989..994] found)
          (NP-1 (-NONE-:[994..994] *))
          (PP-LOC (IN:[995..997] in)
            (NP (NN:[998..1003] codon) (CD:[1004..1006] 12)))))
      (CC:[1007..1010] and)
      (VP (VBD:[1011..1020] consisted)
        (PP-CLR (IN:[1021..1023] of)
          (NP
            (NP (CD:[1024..1026] 24)
              (NML
                (NML (NN:[1027..1028] G))
                (PP (TO:[1029..1031] to)
                  (NP (NN:[1032..1033] T))))
              (NNS:[1035..1048] transversions))
            (,:[1048..1049] ,)
            (NP (CD:[1050..1052] 12)
              (NML
                (NML (NN:[1053..1054] G))
                (PP (TO:[1055..1057] to)
                  (NP (NN:[1058..1059] A))))
              (NNS:[1060..1071] transitions))
            (,:[1071..1072] ,)
            (NP (CD:[1073..1074] 2)
              (NML
                (NML (NN:[1075..1076] G))
                (PP (TO:[1077..1079] to)
                  (NP (NN:[1080..1081] C))))
              (NNS:[1082..1095] transversions))
            (,:[1095..1096] ,) (CC:[1097..1100] and)
            (NP (CD:[1101..1102] 1)
              (NML
                (NML (JJ:[1103..1109] double) (NN:[1110..1112] GG))
                (PP (TO:[1113..1115] to)
                  (NP (NN:[1117..1119] TT))))
              (NN:[1120..1128] mutation))))))
    (.:[1128..1129] .)))

;sentence 9 Span:1130..1234
;Two other G to T transversions were found in codon 13, and 1 A to C 
;transversion was found in codon 61.
;[1140..1141]:variation-state-original:"G"
;[1145..1146]:variation-state-altered:"T"
;[1147..1160]:variation-type:"transversions"
;[1175..1183]:variation-location:"codon 13"
;[1191..1192]:variation-state-original:"A"
;[1196..1197]:variation-state-altered:"C"
;[1199..1211]:variation-type:"transversion"
;[1225..1233]:variation-location:"codon 61"
(SENT
  (S
    (S
      (NP-SBJ-2 (CD:[1130..1133] Two) (JJ:[1134..1139] other)
        (NML
          (NML (NN:[1140..1141] G))
          (PP (TO:[1142..1144] to)
            (NP (NN:[1145..1146] T))))
        (NNS:[1147..1160] transversions))
      (VP (VBD:[1161..1165] were)
        (VP (VBN:[1166..1171] found)
          (NP-2 (-NONE-:[1171..1171] *))
          (PP-LOC (IN:[1172..1174] in)
            (NP (NN:[1175..1180] codon) (CD:[1181..1183] 13))))))
    (,:[1183..1184] ,) (CC:[1185..1188] and)
    (S
      (NP-SBJ-1 (CD:[1189..1190] 1)
        (NML
          (NML (NN:[1191..1192] A))
          (PP (TO:[1193..1195] to)
            (NP (NN:[1196..1197] C))))
        (NN:[1199..1211] transversion))
      (VP (VBD:[1212..1215] was)
        (VP (VBN:[1216..1221] found)
          (NP-1 (-NONE-:[1221..1221] *))
          (PP-LOC (IN:[1222..1224] in)
            (NP (NN:[1225..1230] codon) (CD:[1231..1233] 61))))))
    (.:[1233..1234] .)))

;sentence 10 Span:1235..1360
;The data showed that gender did not seem to  affect the incidence and the
;types of the K-ras mutations or amino acid changes.
;[1322..1327]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (DT:[1235..1238] The) (NNS:[1239..1243] data))
    (VP (VBD:[1244..1250] showed)
      (SBAR (IN:[1251..1255] that)
        (S
          (NP-SBJ-1 (NN:[1256..1262] gender))
          (VP (VBD:[1263..1266] did) (RB:[1267..1270] not)
            (VP (VB:[1271..1275] seem)
              (S
                (NP-SBJ-1 (-NONE-:[1275..1275] *))
                (VP (TO:[1276..1278] to)
                  (VP (VB:[1280..1286] affect)
                    (NP
                      (NP
                        (NP (DT:[1287..1290] the) (NN:[1291..1300] incidence))
                        (CC:[1301..1304] and)
                        (NP (DT:[1305..1308] the) (NNS:[1309..1314] types)))
                      (PP (IN:[1315..1317] of)
                        (NP
                          (NP (DT:[1318..1321] the) (NN:[1322..1327] K-ras)
                              (NNS:[1328..1337] mutations))
                          (CC:[1338..1340] or)
                          (NP (JJ:[1341..1346] amino) (NN:[1347..1351] acid)
                              (NNS:[1352..1359] changes)))))))))))))
    (.:[1359..1360] .)))

;sentence 11 Span:1362..1550
;Examination of the mutations in adenocarcinomas in relation to overall
;survival  showed no difference in adenocarcinomas with K-ras mutations
;compared with  K-ras-negative adenocarcinomas.
;[1394..1409]:malignancy:"adenocarcinomas"
;[1467..1482]:malignancy:"adenocarcinomas"
;[1488..1493]:gene-rna:"K-ras"
;[1519..1524]:gene-rna:"K-ras"
;[1534..1549]:malignancy:"adenocarcinomas"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1362..1373] Examination))
      (PP (IN:[1374..1376] of)
        (NP
          (NP (DT:[1377..1380] the) (NNS:[1381..1390] mutations))
          (PP (IN:[1391..1393] in)
            (NP (NNS:[1394..1409] adenocarcinomas)))))
      (PP (IN:[1410..1412] in)
        (NP
          (NP (NN:[1413..1421] relation))
          (PP (TO:[1422..1424] to)
            (NP (JJ:[1425..1432] overall) (NN:[1433..1441] survival))))))
    (VP (VBD:[1443..1449] showed)
      (NP (DT:[1450..1452] no) (NN:[1453..1463] difference))
      (PP (IN:[1464..1466] in)
        (NP
          (NP
            (NP (NNS:[1467..1482] adenocarcinomas))
            (PP (IN:[1483..1487] with)
              (NP (NN:[1488..1493] K-ras) (NNS:[1494..1503] mutations))))
          (VP (VBN:[1504..1512] compared)
            (NP (-NONE-:[1512..1512] *))
            (PP-CLR (IN:[1513..1517] with)
              (NP
                (ADJP (NN:[1519..1524] K-ras) (HYPH:[1524..1525] -)
                      (JJ:[1525..1533] negative))
                (NNS:[1534..1549] adenocarcinomas)))))))
    (.:[1549..1550] .)))

;sentence 12 Span:1551..1780
;However, the substitution of the wild-type GGT  (glycine) at codon 12 with a
;GTT (valine) or a CGT (arginine) showed a strong  trend (P = 0.07) toward a
;poorer prognosis compared with wild-type or other  amino acid substitutions.
;[1564..1576]:variation-type:"substitution"
;[1594..1597]:variation-state-original:"GGT"
;[1600..1607]:variation-state-original:"glycine"
;[1612..1620]:variation-location:"codon 12"
;[1628..1631]:variation-state-altered:"GTT"
;[1633..1639]:variation-state-altered:"valine"
;[1646..1649]:variation-state-altered:"CGT"
;[1651..1659]:variation-state-altered:"arginine"
;[1755..1779]:variation-type:"amino acid substitutions"
(SENT
  (S
    (ADVP (RB:[1551..1558] However))
    (,:[1558..1559] ,)
    (NP-SBJ
      (NP (DT:[1560..1563] the) (NN:[1564..1576] substitution))
      (PP (IN:[1577..1579] of)
        (NP (DT:[1580..1583] the)
          (NML (JJ:[1584..1588] wild) (HYPH:[1588..1589] -)
               (NN:[1589..1593] type))
          (NN:[1594..1597] GGT)
          (PRN (-LRB-:[1599..1600] -LRB-)
            (NP (NN:[1600..1607] glycine))
            (-RRB-:[1607..1608] -RRB-))))
      (PP-LOC (IN:[1609..1611] at)
        (NP (NN:[1612..1617] codon) (CD:[1618..1620] 12)))
      (PP (IN:[1621..1625] with)
        (NP
          (NP (DT:[1626..1627] a) (NN:[1628..1631] GTT)
            (PRN (-LRB-:[1632..1633] -LRB-)
              (NP (NN:[1633..1639] valine))
              (-RRB-:[1639..1640] -RRB-)))
          (CC:[1641..1643] or)
          (NP (DT:[1644..1645] a) (NN:[1646..1649] CGT)
            (PRN (-LRB-:[1650..1651] -LRB-)
              (NP (NN:[1651..1659] arginine))
              (-RRB-:[1659..1660] -RRB-))))))
    (VP (VBD:[1661..1667] showed)
      (NP
        (NP (DT:[1668..1669] a) (JJ:[1670..1676] strong) (NN:[1678..1683] trend)
          (PRN (-LRB-:[1684..1685] -LRB-)
            (S
              (NP-SBJ (NN:[1685..1686] P))
              (VP (SYM:[1687..1688] =)
                (NP (CD:[1689..1693] 0.07))))
            (-RRB-:[1693..1694] -RRB-)))
        (PP (IN:[1695..1701] toward)
          (NP (DT:[1702..1703] a) (JJR:[1704..1710] poorer)
              (NN:[1711..1720] prognosis))))
      (VP (VBN:[1721..1729] compared)
        (NP (-NONE-:[1729..1729] *))
        (PP-CLR (IN:[1730..1734] with)
          (NP
            (NP
              (NML (JJ:[1735..1739] wild) (HYPH:[1739..1740] -)
                   (NN:[1740..1744] type))
              (NML-1 (-NONE-:[1744..1744] *P*)))
            (CC:[1745..1747] or)
            (NP (JJ:[1748..1753] other)
              (NML-1 (JJ:[1755..1760] amino) (NN:[1761..1765] acid)
                     (NNS:[1766..1779] substitutions)))))))
    (.:[1779..1780] .)))

;sentence 13 Span:1781..1936
;Substitution of the wild-type glycine for aspartate  (GAT) showed a strong
;trend (P = 0.06) for a better outcome than the valine or  arginine
;substitution.
;[1781..1793]:variation-type:"Substitution"
;[1811..1818]:variation-state-original:"glycine"
;[1823..1832]:variation-state-altered:"aspartate"
;[1835..1838]:variation-state-altered:"GAT"
;[1903..1909]:variation-state-altered:"valine"
;[1914..1922]:variation-state-altered:"arginine"
;[1923..1935]:variation-type:"substitution"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1781..1793] Substitution))
      (PP (IN:[1794..1796] of)
        (NP (DT:[1797..1800] the)
          (NML (JJ:[1801..1805] wild) (HYPH:[1805..1806] -)
               (NN:[1806..1810] type))
          (NN:[1811..1818] glycine)))
      (PP (IN:[1819..1822] for)
        (NP (NN:[1823..1832] aspartate)
          (PRN (-LRB-:[1834..1835] -LRB-)
            (NP (NN:[1835..1838] GAT))
            (-RRB-:[1838..1839] -RRB-)))))
    (VP (VBD:[1840..1846] showed)
      (NP (DT:[1847..1848] a) (JJ:[1849..1855] strong) (NN:[1856..1861] trend)
        (PRN (-LRB-:[1862..1863] -LRB-)
          (S
            (NP-SBJ (NN:[1863..1864] P))
            (VP (SYM:[1865..1866] =)
              (NP (CD:[1867..1871] 0.06))))
          (-RRB-:[1871..1872] -RRB-)))
      (PP (IN:[1873..1876] for)
        (NP
          (NP (DT:[1877..1878] a) (JJR:[1879..1885] better)
              (NN:[1886..1893] outcome))
          (PP (IN:[1894..1898] than)
            (NP (DT:[1899..1902] the)
              (NML
                (NML (NN:[1903..1909] valine)
                  (NML-1 (-NONE-:[1909..1909] *P*)))
                (CC:[1910..1912] or)
                (NML (NN:[1914..1922] arginine)
                  (NML-1 (NN:[1923..1935] substitution)))))))))
    (.:[1935..1936] .)))

;sentence 14 Span:1937..2157
;Although these trends will require larger patient  populations for
;verification, these data suggest that the prognostic  significance of K-ras
;mutations may depend on the amino acid substitution in the  p21(ras)
;protein.
;[2074..2079]:gene-rna:"K-ras"
;[2108..2131]:variation-type:"amino acid substitution"
;[2140..2148]:gene-protein:"p21(ras)"
(SENT
  (S
    (SBAR-ADV (IN:[1937..1945] Although)
      (S
        (NP-SBJ (DT:[1946..1951] these) (NNS:[1952..1958] trends))
        (VP (MD:[1959..1963] will)
          (VP (VB:[1964..1971] require)
            (NP (JJR:[1972..1978] larger) (NN:[1979..1986] patient)
                (NNS:[1988..1999] populations))
            (PP (IN:[2000..2003] for)
              (NP (NN:[2004..2016] verification)))))))
    (,:[2016..2017] ,)
    (NP-SBJ (DT:[2018..2023] these) (NNS:[2024..2028] data))
    (VP (VBP:[2029..2036] suggest)
      (SBAR (IN:[2037..2041] that)
        (S
          (NP-SBJ
            (NP (DT:[2042..2045] the) (JJ:[2046..2056] prognostic)
                (NN:[2058..2070] significance))
            (PP (IN:[2071..2073] of)
              (NP (NN:[2074..2079] K-ras) (NNS:[2080..2089] mutations))))
          (VP (MD:[2090..2093] may)
            (VP (VB:[2094..2100] depend)
              (PP-CLR (IN:[2101..2103] on)
                (NP
                  (NP (DT:[2104..2107] the)
                    
                    (NML (JJ:[2108..2113] amino) (NN:[2114..2118] acid))
                    (NN:[2119..2131] substitution))
                  (PP-LOC (IN:[2132..2134] in)
                    (NP (DT:[2135..2138] the) (NN:[2140..2148] p21-LRB-ras-RRB-)
                        (NN:[2149..2156] protein))))))))))
    (.:[2156..2157] .)))

;section 15 Span:2161..2205
;PMID: 9816185 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2161..2165] PMID) (::[2165..2166] :) (CD:[2167..2174] 9816185)
        (IN:[2175..2176] -LSB-) (NNP:[2176..2182] PubMed) (HYPH:[2183..2184] -)
        (JJ:[2185..2192] indexed) (IN:[2193..2196] for)
        (NNP:[2197..2205] MEDLINE-RSB-)))
